Week In Review: Tianjin CanSino Staging $160.5 Million Hong Kong IPO

CanSino is the seventh China biopharma, and the first vaccine company, to IPO in Hong Kong under its pre-revenue … Greater China Healthcare practice at McKinsey & Company. The Cambrian Explosion …
( read original story …)

---